Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Multi-omics Approach to Examine Symptoms and Medication Adherence in Women with Breast Cancer

Award Number: F99CA253771
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 08/01/2020
PERIOD OF PERFORMANCE END DATE: 07/31/2022

Group Awards By:

View Award Description

A Multi-omics Approach to Examine Symptoms and Medication Adherence in Women with Breast Cancer - A Multi-Omics Approach to Examine Symptoms and Medication Adherence in Women with Breast Cancer Breast cancer is most prevalent in postmenopausal women, and 3.4 million U.S. women are survivors. Most women with breast cancer are postmenopausal at the time of diagnosis, and at least 70% of tumors are hormone receptor positive (HR+). Aromatase inhibitors effectively prevent BC recurrence, and current standard includes adjuvant aromatase inhibitor (AI) therapy in a once daily standard dose regimen for a minimum of five years. However, AI adherence is a significant problem. Up to one third of women do not fill their initial AI prescription, adherence to AIs averaged 48% in the first year, and adherence decreases in subsequent 2-5 years. AI-attributed symptoms are the leading reason for not adhering to AI regimens and a major barrier to AI adherence. Moreover, AI-related symptom type and severity are highly variable among women. The source of symptom variability is unknown. The etiology of symptoms experienced during AI therapy may have biological underpinnings, yet little is known about factors in AI (anastrozole, letrozole, exemestane) absorption, distribution, metabolism, and elimination (ADME) pathways and the resulting symptoms. Symptoms and adherence, especially their relationship to each other, have not been well-characterized temporally. Further, potential biologic mechanisms related to AI absorption, distribution, metabolism, and elimination (ADME) for AIs have not been fully characterized. The dissertation project (F99) will examine temporal patterns of AI symptoms and adherence and their relationship over the first 18 months of AI therapy. It will also explore the role of genotypic (ADME) and phenotypic factors in symptoms experienced and AI adherence. The postdoctoral project (K00 phase) will incorporate two additional molecular methods—microbiomics and exosomics. They will be described and their potential role in AI symptoms experienced and adherence will be explored. The purpose of the proposed F99/K00 training and research is to utilize a biobehavioral, multi-omics approach to gain a deeper understanding of the complex web of AI symptoms and adherence, including the temporal variability among women and the interplay between symptoms and adherence. It will provide insight into potential biological mechanisms by describing molecular and phenotypic characteristics associated with symptoms and adherence. Ultimately, this research will inform future symptom management and adherence interventions and their timing.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$32,129 )
2023	2021	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Cause and Prevention Research	000	2	5/15/2023	NON-COMPETING CONTINUATION	-$32,129
														Subtotal = -$32,129

Issue Date FY: 2021 ( Subtotal = $46,036 )
2021	2021	UNIVERSITY OF PITTSBURGH, THE	4200 5TH AVE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Cause and Prevention Research	000	2	7/20/2021	NON-COMPETING CONTINUATION	$46,036
														Subtotal = $46,036

Issue Date FY: 2020 ( Subtotal = $47,020 )
2020	2020	UNIVERSITY OF PITTSBURGH THE	3520 FIFTH AVE	PITTSBURGH	PA	15213	ALLEGHENY	USA	Cancer Cause and Prevention Research	000	1	7/24/2020	NEW	$47,020
														Subtotal = $47,020

Grand Total All Awards = $60,927

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Multi-omics Approach to Examine Symptoms and Medication Adherence in Women with Breast Cancer

Award Number: F99CA253771

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 08/01/2020

PERIOD OF PERFORMANCE END DATE: 07/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer